Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 2OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Gliosarcoma 1Glioblastoma 1

Interventions

Cyclophosphamide 4Cisplatin 3pembrolizumab 2fludarabine 2apatinib 2XELOX 2S 1 (combination) 2Paclitaxel 2Oxaliplatin 2Nivolumab 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Irinotecan 2Injections 2Gemcitabine 2Fulvestrant 2Epirubicin 2Drug Therapy 2Boron Neutron Capture Therapy 2titanium silicide 1tislelizumab 1surufatinib 1sintilimab 1pegfilgrastim 1nimotuzumab 1ipatasertib 1ferumoxides 1famitinib 1eribulin 1dalpiciclib 1dactolisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER_GOV × dactolisib × Clear all
NCT02430363 2016-02-24

Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475

Medical Research Council

Phase 1/2 Unknown
58 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡